Anti-α-Synuclein Antibody, clone 2F12 ZooMAb® Mouse Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 2F12 is a ZooMAb® Mouse recombinant monoclonal antibody that specifically detects a-Synuclein. It target an epitope within 11 amino acids from the C-terminal region.
• Immunogen: Purified full-length human erythrocyte a-synuclein.
• Application: Quality Control TestingEvaluated by Western Blotting in human thalamus tissue lysate.Western Blotting Analysis: A 1:1,000 dilution of this antibody detected -Synuclein in human thalamus tissue lysate.Tested applicationsWestern Blotting Analysis: A 1:1,000 dilution from a representative lot detected -Synuclein in human brain tissue lysate.Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected -Synuclein in human cerebral cortex and rat cerebellum tissue sections.Immunoprecipitation Analysis: A representative lot of mouse monoclonal antibody (clone 2F12) immunoprecipitated -Synuclein in Immunoprecipitation applications (Courtesy of Tim Bartels, Ph.D., Brigham and Women′s Hospital, Boston, MA).Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected -Synuclein in E18 mouse cortical cells.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
• Target description: Alpha-synuclein (UniProt: P37840; also known as Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, NACP) is encoded by the SNCA (also known as NACP; PARK1) gene (Gene ID: 6622) in human. a-synuclein is abundantly expressed in the brain and is found in a classic amyloid fibril form within the intra-neuronal Lewy body deposits of Parkinson′s disease brains. In its monomeric form it participates in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. It acts by increasing local Ca2+ release from microdomains, which is essential for the enhancement of ATP-induced exocytosis. In its multimeric form it acts as a molecular chaperone assisting in the folding of synaptic fusion components called SNAREs at presynaptic membrane. It is also involved in the regulation of dopamine release and transport. It is also reported to reduce neuronal responsiveness to various apoptotic stimuli, leading to reduced caspase-3 activation. Post-translationally it can be phosphorylated, predominantly on serine residues. Phosphorylation of serine 129 is reported to be selective and extensive in synucleinopathy lesions. Genetic alterations of SNCA gene are reported to result in aberrant polymerization into fibrils, which is associated with several neurodegenerative diseases (synucleinopathies). Mutations in SNCA gene are also known to Parkinson′s disease characterized by bradykinesia, resting tremor, muscular rigidity, and postural instability. The pathology of Parkinson s disease involves progressive loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies in surviving neurons in various areas of the brain. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Huang, CC., et al. (2018). J. Cell Sci. 131(23); jcs213017; Burre, J., et al. (2010). Science. 329(5999). 1663-1667).
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.